Philippe De Wals

Summary

Country: Canada

Publications

  1. pmc Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010
    Jean Baptiste Le Meur
    Quebec Heart and Lung Institute Research Centre, Quebec City, Canada Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Int J Circumpolar Health 73:22691. 2014
  2. doi request reprint Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada Quebec National Public Health Institute Institut national de Santé publique du Québec, Quebec City, Canada Quebec University Hospital Research Centre, Quebec City, Canada Electronic address
    Vaccine 32:1501-6. 2014
  3. doi request reprint Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Vaccine 30:6416-20. 2012
  4. ncbi request reprint Impact of folic acid food fortification on the birth prevalence of lipomyelomeningocele in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:106-9. 2008
  5. doi request reprint Spina bifida before and after folic acid fortification in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:622-6. 2008
  6. ncbi request reprint Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Laval University, Quebec, Canada
    Hum Vaccin 6:212-8. 2010
  7. ncbi request reprint Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis
    Philippe De Wals
    Department of Preventive and Social Medicine, Laval University, Quebec City, Canada
    Vaccine 25:5433-40. 2007
  8. ncbi request reprint Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada
    Genevieve Deceuninck
    Public Health Research Unit, Quebec University Hospital Research Centre, Quebec City, Canada
    Pediatr Infect Dis J 29:546-9. 2010
  9. doi request reprint Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 30:566-9. 2011
  10. doi request reprint Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 27:963-8. 2008

Collaborators

Detail Information

Publications34

  1. pmc Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010
    Jean Baptiste Le Meur
    Quebec Heart and Lung Institute Research Centre, Quebec City, Canada Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Int J Circumpolar Health 73:22691. 2014
    ..At the same time, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine immunization programme of infants, with catch-up for children up to 4 years of age...
  2. doi request reprint Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada Quebec National Public Health Institute Institut national de Santé publique du Québec, Quebec City, Canada Quebec University Hospital Research Centre, Quebec City, Canada Electronic address
    Vaccine 32:1501-6. 2014
    ..The program was implemented in December 2004 with a catch-up for children <5 years. PCV-7 was first used and replaced, respectively, by PCV-10 in 2009 and by PCV-13 in 2011...
  3. doi request reprint Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Vaccine 30:6416-20. 2012
    ..In the province of Quebec, Canada, PHiD-CV was introduced in the summer of 2009, replacing the 7-valent CRM197 vaccine (PCV-7). Transition to the new vaccine was recommended regardless of the number of PCV7 doses already administered...
  4. ncbi request reprint Impact of folic acid food fortification on the birth prevalence of lipomyelomeningocele in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:106-9. 2008
    ..This study was performed to assess the prevalence of LMMC in Canada in relation to the timing of food fortification...
  5. doi request reprint Spina bifida before and after folic acid fortification in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
    Birth Defects Res A Clin Mol Teratol 82:622-6. 2008
    ..A multicentric study was carried out to assess the impact of this policy on the frequency of NTDs. The present analysis focused on spina bifida...
  6. ncbi request reprint Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Laval University, Quebec, Canada
    Hum Vaccin 6:212-8. 2010
    ..70-0.90). Three doses of RB administered at the age of 8-10 years induce a 10 years long-lasting immunity in virtually all vaccinees. The booster does not appear necessary on a 10 years perspective...
  7. ncbi request reprint Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis
    Philippe De Wals
    Department of Preventive and Social Medicine, Laval University, Quebec City, Canada
    Vaccine 25:5433-40. 2007
    ..One dose of serogroup C meningococcal conjugate vaccine (MCV-C) at 12 months of age is the most common immunization schedule in Canada, but immunity may wane over time...
  8. ncbi request reprint Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada
    Genevieve Deceuninck
    Public Health Research Unit, Quebec University Hospital Research Centre, Quebec City, Canada
    Pediatr Infect Dis J 29:546-9. 2010
    ....
  9. doi request reprint Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 30:566-9. 2011
    ..In 2002, 1 C-MCV dose was routinely offered to children 12 months of age...
  10. doi request reprint Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 27:963-8. 2008
    ....
  11. doi request reprint Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Quebec, Canada
    JAMA 308:175-81. 2012
    ..In fall 2009 in Quebec, Canada, an immunization campaign was launched against the 2009 influenza A(H1N1) pandemic strain, mostly using an AS03 adjuvant vaccine. By the end of the year, 57% of the 7.8 million residents had been vaccinated...
  12. pmc The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains
    Rodica Gilca
    Institut National de Sante Publique du Quebec, Quebec City, Quebec, Canada
    PLoS ONE 7:e50659. 2012
    ....
  13. ncbi request reprint Epidemiology of Guillain-Barré syndrome in the province of Quebec
    Genevieve Deceuninck
    Public Health Research Unit, Quebec University Hospital Centre, Quebec City, Canada
    Can J Neurol Sci 35:472-5. 2008
    ..In the province of Quebec, a population-based study of Guillain-Barré syndrome (GBS) was conducted at the time of a mass immunization campaign against meningococcal disease, in 2001...
  14. ncbi request reprint Meningococcal C vaccines: the Canadian experience
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University and Quebec National Public Health Institute, Quebec, Canada
    Pediatr Infect Dis J 23:S280-4. 2004
    ....
  15. ncbi request reprint Uptake of pneumococcal conjugate vaccine: methodological issues in measurement and impact of publicly funded programs
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC
    Can J Public Health 100:413-6. 2009
    ..In Quebec, the pneumococcal conjugate vaccine was available on the private market as early as 2001 and has been included in the publicly funded immunization program since December 2004...
  16. doi request reprint Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec, Quebec, Canada
    Clin Ther 31:2152-69. 2009
    ..New health economic models are required to model the impact of PHiD-CV and compare its effectiveness with PCV-7...
  17. doi request reprint Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later
    Vladimir Gilca
    Institut National de Sante Publique du Quebec, Laval University, Quebec, Canada
    Vaccine 27:6048-53. 2009
    ..The excellent anamnestic response observed after the booster dose demonstrates the persistence of immunity in virtually all young adults vaccinated at the age of 8-10 with three paediatric doses of Engerix-B...
  18. ncbi request reprint Impact of a mass immunization campaign to control an outbreak of severe respiratory infections in Nunavik, northern Canada
    Abdoul Aziz Ndiaye
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Int J Circumpolar Health 65:297-304. 2006
    ....
  19. ncbi request reprint Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation
    Philippe De Wals
    Faculty of Medicine, Laval University, and Quebec National Institute of Public Health, Canada
    Vaccine 24:3500-4. 2006
    ..Existing routine immunization schedules may not be optimal and should be designed to achieve the highest level of protection using the lowest number of doses...
  20. ncbi request reprint Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec, Canada
    Clin Infect Dis 40:1116-22. 2005
    ....
  21. ncbi request reprint Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine
    Philippe De Wals
    Quebec National Public Health Institute and Department of Preventive and Social Medicine, Laval University, Quebec City, Quebec
    JAMA 292:2491-4. 2004
    ..Meningococcal polysaccharide vaccines are of limited effectiveness. New protein-polysaccharide conjugate vaccines have yet to be evaluated in field conditions...
  22. doi request reprint Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions
    Philippe De Wals
    Department of Preventive and Social Medicine, Laval University, Quebec City, Canada
    Vaccine 27:3223-7. 2009
    ..In 2001, a mass immunization campaign was implemented in the province of Quebec, Canada, using a new serogroup C meningococcal conjugate vaccine (C-MCV)...
  23. doi request reprint Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, 1050 avenue de la Medecine, Quebec City, G1V 0A6, Canada
    Expert Rev Vaccines 10:55-62. 2011
    ..Vaccine uptake rate is high and, although a reduced number of doses are recommended for several vaccines, program effectiveness is highly satisfactory, as shown for hepatitis B, meningococcal and pneumococcal diseases...
  24. ncbi request reprint Immunization strategies for the control of serogroup C meningococcal disease in developed countries
    Philippe De Wals
    Laval University, and Quebec National Public Health Institute, Department of Social and Preventive Medicine, Pavillon de l Est, 2180 chemin Sainte Foy, Quebec G1K 7P4, Canada
    Expert Rev Vaccines 5:269-75. 2006
    ..A schedule consisting of a first dose around 1 year of age and a second dose around 12 years of age seems to be a very cost-effective option in most epidemiological scenarios...
  25. ncbi request reprint Reduction in neural-tube defects after folic acid fortification in Canada
    Philippe De Wals
    Laval University, Quebec, Canada
    N Engl J Med 357:135-42. 2007
    ..We assessed changes in the prevalence of neural-tube defects in Canada before and after food fortification with folic acid was implemented...
  26. doi request reprint Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Clin Infect Dis 46:e75-7. 2008
    ..In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected...
  27. ncbi request reprint Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Pavillon de l Est, 2180 chemin Sainte Foy, Quebec, Que, Canada G1K 7P4
    Vaccine 22:1233-40. 2004
    ..If vaccine-induced immunity is waning rapidly, mass immunization or routine vaccination with booster dose(s) would be the best control options...
  28. pmc The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine
    Adrienne Morrow
    Department of Social and Preventive Medicine, Laval University, Quebec City
    Can J Infect Dis Med Microbiol 18:121-7. 2007
    ..To evaluate the impact in Canada, it is essential to have an estimate of the burden of pneumococcal disease before routine use of the vaccine...
  29. pmc Trends of hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003
    Magalie Canuel
    Department of Social and Preventive Medicine, Laval University, Quebec, Canada
    BMC Infect Dis 7:31. 2007
    ..This study estimated the year and age specific hospitalization rates and distribution of risk factors for HA in Quebec, Canada, between 1990 and 2003...
  30. pmc Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire
    Eve Dube
    Quebec National Institute of Public Health, d Estimauville, Quebec City, G1E 7G9, Canada
    Health Qual Life Outcomes 8:75. 2010
    ..The negative consequences of acute otitis media (AOM) on the quality of life (QOL) of children and their families need to be measured to assess benefits of preventive interventions...
  31. doi request reprint How to compare the efficacy of conjugate vaccines to prevent acute otitis media?
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Pavillon de l Est, 2180 chemin Sainte Foy, Suite 1108, Quebec City, Canada G1K 7P4
    Vaccine 27:2877-83. 2009
    ..More studies on the current aetiology of AOM need to be performed to accurately predict the marginal benefit of a switch from PCV7-CRM(197) to the newly licensed PCV10-HiD-DiT or to the future PCV13-CRM(197)...
  32. ncbi request reprint Reviews examining sugar-sweetened beverages and body weight: correlates of their quality and conclusions
    José Massougbodji
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada JM and PDW, and the Quebec Heart and Lung Institute Research Center, Quebec City, Canada YLB, RF, and PDW
    Am J Clin Nutr 99:1096-104. 2014
    ..The role of sugar-sweetened beverages (SSBs) in increasing obesity is of great scientific, clinical, and public health interest. Many reviews have been published on this topic in recent years with very different conclusions...
  33. ncbi request reprint Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Que, Canada G1K 7P4
    Vaccine 21:3757-64. 2003
    ..Vaccination would result in net savings for society, if vaccine cost is less than 30 dollars per dose. Economic indicators of catch-up programs are less favorable than for routine infant immunization...
  34. ncbi request reprint Validity of death and stillbirth certificates and hospital discharge summaries for the identification of neural tube defects in Quebec City
    Fassiatou Tairou
    Department of Social and Preventive Medicine, Laval University, Quebec City, Quebec, Canada
    Chronic Dis Can 27:120-4. 2006
    ....